Rodriquez F Wilcox B . Radiation sensitizing effects of Taxotere (RP56976) (Abstr. #2991) . Proc Am Assoc Cancer Res 1992 ; 33 : 500 . 14 Burkhart C Berman J Swindell C . Relationship between the structure of taxol and other taxanes ion
Search Results
Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara
Although some evidence exists to support the use of clinical factors such as performance status and weight loss to predict response and toxicity to therapy in non-small cell lung cancer (NSCLC) patients, researchers have shown little prospective data on the use of molecular markers to facilitate selection of specific chemotherapy or new molecularly targeted agents in this patient population. Breast cancer exemplifies the growing role that molecular markers are playing, not only as prognostic factors, but also in predicting response to targeted treatments such as hormonal therapy, and more recently, trastuzumab (Herceptin). Although several studies have examinedmolecular markers in lung cancer and have shown promising potential value, these studies were retrospective and require prospective validation. To identify molecular markers that reliably predict response and to be able to individualize cytotoxic and targeted therapy for NSCLC patients are the ultimate goals of future trials. This article focuses on a selected number of promising markers under study in lung cancer, including those thought to play roles in response to DNA damaging chemotherapy (excision repair cross-complementing [ERCC1], xeroderma pigmentosum group D [XPD]), taxane resistance (-tubulin III), antimetabolite therapy (RRM1), irinotecan metabolism (UGT1A1) and epidermal growth factor receptor (EGFR) pathway inhibition. To date, none of these markers can be recommended for routine use in clinical practice.
Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force
suppression/ablation versus both difficult. Additionally, few trials compared ovarian suppression to anthracycline-containing or taxane-containing regimens commonly used today. Finally, trials were not always limited to patients with ER-positive disease, and
Matthieu Picard, Ursula A. Matulonis, and Mariana Castells
Ovarian cancer is the leading cause of death among gynecologic malignancies and ranks fifth in overall cancer-related mortality among women in the United States. 1 Chemotherapy, particularly with a taxane and platinum combination, is key to
Jessica A. Davis, Zhanglin Lin Cui, Madiha Ghias, Xiaohong Li, Robert Goodloe, Astra M. Liepa, Kenyon Ogburn, and Lisa M. Hess
(95% CI: 12.07, 13.6). The most common 1L regimens were fluoropyrimidine + oxaliplatin (n=651, 22.4%), platinum (ie, cisplatin or carboplatin) + taxane (n=511, 17.5%), and single-agent fluoropyrimidine (n=280, 9.6%). 1,230 patients received second line
in HER2-negative breast cancers, whereas non-anthracycline–based regimens, especially the combination of docetaxel and cyclophosphamide (TC), accounts for 45%. The vast majority of patients in this setting now receive taxane-based treatments. Among
Matthew G. Fury and David G. Pfister
incurable with surgery or radiation, platinum agents, taxanes, methotrexate, 5-fluorouracil (5-FU), and cetuximab are the drugs that medical oncologists most commonly consider for palliative cancer-directed treatment. Available data supporting the observed
Angela Jain, Paula D. Ryan, and Michael V. Seiden
chemotherapy typically with a platinum/taxane-based regimen if recommended in the guidelines. Figure 2 Carcinoembryonic antigen (CEA) trend. Similar to patients with colorectal cancers (CRCs), those with mOCs tend to have serum elevations of CEA
Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood
Chemotherapy consisted of either cisplatin > 80 mg/m 2 or carboplatin at an area under the curve of at least 5 combined with at least one other drug. Most patients received either platinum/gemcitabine or platinum/taxane combinations. Median overall
Corina van den Hurk, Wouter Dercksen, Birgit Vriens, and Wim Breed
postinfusion cooling time 90 minutes. An exception was for docetaxel, for which 20 minutes postinfusion cooling time was used in recent years. Scalp cooling efficacy varied from above 80% for taxanes monotherapy to below 10% for the combination of docetaxel
